Government
AstronauTx biotech closes £48m Series A for Alzheimer’s drugs
By Timothy Adler on Growth Business – Your gateway to entrepreneurial success
London-based biotech developing drugs to cure Alzheimer’s, a disease which…
By Timothy Adler on Growth Business – Your gateway to entrepreneurial success
London-based biotech AstronauTx has closed £48 million Series A financing to create new treatments for Alzheimer’s disease.
AstronauTx is developing drugs to correct the disrupted physiology of the brain, partly through improving the support function of astrocytes, the most abundant cell type in the brain.
Novartis Venture Fund led the financing with Brandon Capital, Bristol Myers Squibb, EQT Life Sciences investing from the LSP Dementia Fund, MPM Capital alongside current investor the Dementia Discovery Fund.
The company was spun out of University College London in 2019, with seed funding from the £250 million Dementia Discovery Fund with additional seed-stage funding from the UCL Technology Fund and the UK Future Fund.
Dundee named top university for spinout success – A report has found that 60% of the top ten spinout universities are based outside the golden triangle
Although AstronauTx does not expect any of its drugs to reach clinics for at least three or four years, the financing is a step towards helping millions of sufferers.
The company aimed to select its first lead compound for pre-clinical development in a year with clinical trials taking place between three to four years in the future, David Reynolds, chief executive of AstronauTx, told the Financial Times.
AstronauTx’s first patient products are not likely to be on the market until the 2030s.
Investment in university spinouts drops for second consecutive year – Investment in UK university spinouts looks set to fall dramatically this year, following a year-on-year drop to £2.3bn in 2022, down from £2.7bn the year before
According to the World Health Organization, 55 million people worldwide have dementia and there are almost 10 million new cases every year, making it one of the most pressing global health problems.
The overall annual cost of Alzheimer’s to the world economy, including care costs, healthcare costs, lost productivity during earl onset, and people taking time away from their careers to become carers, is expected to reach £90bn a year by 2040.
Dr Ruth McKernan, co-founder of AstronauTx, said: “We now know that the processes causing Alzheimer’s and other similar diseases are modifiable.
“Progress towards a compendium of new drugs against these devastating diseases is thankfully well underway. Our treatments will be oral drugs, applicable across multiple neurodegenerative conditions, and additive with mechanisms that are currently in late-stage development.”
Further reading
British investors ready to invest £1.4bn in university spinouts – Cambridge Innovation Capital takes top spot as biggest investor in university spinouts with £500m under management, with new entrant Northern Powerhouse raising £300m to invest in northern university tech start-ups
The post AstronauTx biotech closes £48m Series A for Alzheimer’s drugs appeared first on Growth Business.
clinical trials
world health organization
fund
biotech
life sciences
healthcare
Here Are the Champions! Our Top Performing Stories in 2023
It has been quite a year – not just for the psychedelic industry, but also for humanity as a whole. Volatile might not be the most elegant word for it,…
AI can already diagnose depression better than a doctor and tell you which treatment is best
Artificial intelligence (AI) shows great promise in revolutionizing the diagnosis and treatment of depression, offering more accurate diagnoses and predicting…
Scientists use organoid model to identify potential new pancreatic cancer treatment
A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer…
